{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:22:41Z","timestamp":1789392161464,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:p>Vancomycin, a first-line drug for treating methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> infections, is associated with acute kidney injury (AKI). This study involved an evaluation of biomarkers for AKI detection and their comparison with traditional serum creatinine (SCr). We prospectively enrolled patients scheduled to receive intravenous vancomycin for methicillin-resistant <jats:italic toggle=\"yes\">S aureus<\/jats:italic> infection. Blood samples for pharmacokinetic assessment and SCr and cystatin C (CysC) measurements were collected at baseline and on days 3, 7, and 10 from the initiation of vancomycin administration (day 1). Urinary biomarkers, including kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin, and clusterin, were collected from days 1 to 7 and adjusted for urinary creatinine levels. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Of the 42 patients, 6 experienced vancomycin-induced AKI. On day 7, the change from baseline eGFR using CysC (\u0394eGFR<jats:sub>CysC<\/jats:sub>) showed a stronger correlation with vancomycin area under the curve (<jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u2005\u22120.634, <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>&lt;\u2005.001) than that using SCr (\u0394eGFR<jats:sub>SCr<\/jats:sub>; <jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u2005\u22120.437, <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.020). \u0394eGFR<jats:sub>SCr<\/jats:sub> showed no significant correlation with vancomycin pharmacokinetic in patients with body mass index\u2005\u226523. The median (interquartile range) level of KIM-1 (\u03bcg\/mg) was significantly higher in the AKI group (0.006 [0.005\u20130.008]) than in the non-AKI group (0.004 [0.001\u20130.005]) (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.039, Mann\u2013Whitney <jats:italic toggle=\"yes\">U<\/jats:italic> test), with area under the receiver operating characteristic curve (95% confidence interval) of 0.788 (0.587\u20130.990). Serum CysC, particularly in overweight individuals or those with obesity, along with urinary KIM-1 are important predictors of vancomycin-induced AKI. These results may aid in selecting better biomarkers than traditional SCr for detecting vancomycin-induced AKI.<\/jats:p>","DOI":"10.1097\/md.0000000000039202","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:39:51Z","timestamp":1723228791000},"page":"e39202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Serum and urinary biomarkers of vancomycin-induced acute kidney injury: A prospective, observational analysis"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8302-2488","authenticated-orcid":false,"given":"Sang-In","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon, Republic of Korea"},{"name":"Biomedical Research Institute, Kangwon National University Hospital, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uijeong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sup","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Won","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongmin","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhwa","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjeong","family":"Baek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-3759","authenticated-orcid":false,"given":"Ji In","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-017-0536-3","article-title":"The 6R\u2019s of drug induced nephrotoxicity.","volume":"18","author":"Awdishu","year":"2017","journal-title":"BMC Nephrol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.ackd.2019.08.001","article-title":"Nephrotoxicity of antimicrobials and antibiotics.","volume":"27","author":"Morales-Alvarez","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkz325","article-title":"Mechanisms of antimicrobial-induced nephrotoxicity in children.","volume":"75","author":"Downes","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3390\/ijms22116109","article-title":"The mechanism of drug nephrotoxicity and the methods for preventing kidney damage.","volume":"22","author":"Kwiatkowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/2047-783X-15-12-507","article-title":"Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin?-comparison of pharmacology and clinical efficacy.","volume":"15","author":"Pletz","year":"2010","journal-title":"Eur J Med Res"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/MCC.0000000000000653","article-title":"Drug-induced acute kidney injury: diverse mechanisms of tubular injury.","volume":"25","author":"Perazella","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2016080867","article-title":"Vancomycin-associated cast nephropathy.","volume":"28","author":"Luque","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: core curriculum 2021.","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-021-02588-4","article-title":"Evaluation and enhancement of standard equations for renal function estimation in individuals with components of metabolic disease.","volume":"22","author":"Brunetti","year":"2021","journal-title":"BMC Nephrol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00467-008-1060-2","article-title":"Acute kidney injury in critically ill newborns: what do we know? What do we need to learn?","volume":"24","author":"Askenazi","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e00079","DOI":"10.1128\/AAC.00079-19","article-title":"Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury.","volume":"63","author":"Pais","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250503","first-page":"4203","article-title":"Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as early biomarkers for predicting vancomycin-associated acute kidney injury: a prospective study.","volume":"21","author":"Pang","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.ccx.0000145095.90327.f2","article-title":"Biologic markers for the early detection of acute kidney injury.","volume":"10","author":"Han","year":"2004","journal-title":"Curr Opin Crit Care"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/10408363.2021.1879000","article-title":"Current concepts and advances in biomarkers of acute kidney injury.","volume":"58","author":"Wen","year":"2021","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"F568","DOI":"10.1152\/ajprenal.00399.2009","article-title":"Loss of clusterin expression worsens renal ischemia-reperfusion injury.","volume":"298","author":"Zhou","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nbt0510-436","article-title":"Next-generation biomarkers for detecting kidney toxicity.","volume":"28","author":"Bonventre","year":"2010","journal-title":"Nat Biotechnol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/1389200220666190711114504","article-title":"Serial quantification of urinary protein biomarkers to predict drug-induced acute kidney injury.","volume":"20","author":"Da","year":"2019","journal-title":"Curr Drug Metab"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"c154","DOI":"10.1159\/000312879","article-title":"Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.","volume":"115","author":"Gaspari","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/ijms20205238","article-title":"The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity.","volume":"20","author":"Tanase","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jpids\/piaa078","article-title":"A moving target\u2014vancomycin therapeutic monitoring.","volume":"9","author":"Burns","year":"2020","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2146\/ajhp180034","article-title":"Making the change to area under the curve\u2013based vancomycin dosing.","volume":"75","author":"Heil","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R27-20250503","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Levin","year":"2013","journal-title":"KI Supplements"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.ftd.0000211805.89440.3d","article-title":"Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.","volume":"28","author":"Hermida","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clinbiochem.2007.01.008","article-title":"Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients.","volume":"40","author":"Okamoto","year":"2007","journal-title":"Clin Biochem"},{"key":"R31-20250503","first-page":"500","article-title":"Prediction of the renal elimination of drugs with cystatin C vs creatinine: a systematic review.","volume":"94","author":"Barreto","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00280-005-0012-9","article-title":"Prospective evaluation of carboplatin AUC dosing in patients with a BMI\u2265 27 or cachexia.","volume":"57","author":"Herrington","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"e01487","DOI":"10.1128\/AAC.01487-20","article-title":"Prediction of vancomycin levels using cystatin C in overweight and obese patients: a retrospective cohort study of hospitalized patients.","volume":"65","author":"Teaford","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels.","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/pharmacy8010035","article-title":"Cystatin C: a primer for pharmacists.","volume":"8","author":"Teaford","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/0897190017737895","article-title":"Disagreement in estimates of kidney function for drug dosing in obese inpatients.","volume":"32","author":"Higdon","year":"2019","journal-title":"J Pharm Pract"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/phar.2893","article-title":"Urinary biomarkers as indicators of acute kidney injury in critically ill children exposed to vancomycin.","volume":"44","author":"Spyhalsky","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1752-8062.2008.00053.x","article-title":"Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans.","volume":"1","author":"Vaidya","year":"2008","journal-title":"Clin Transl Sci"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"705636","DOI":"10.3389\/fphar.2021.705636","article-title":"The role of urinary biomarkers as diagnostic and prognostic predictors of acute kidney injury associated with vancomycin.","volume":"12","author":"Sampaio de Souza Garms","year":"2021","journal-title":"Front Pharmacol"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/187152811796117735","article-title":"The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review.","volume":"10","author":"Huang","year":"2011","journal-title":"Inflamm Allergy Drug Targets"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:37:17Z","timestamp":1746319037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":40,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039202","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}